A new framework for defining clinical obesity, proposed by The Lancet Diabetes & Endocrinology Commission, is now being tested in liver disease patients across Asia. In a study published in International Journal of Obesity, researchers evaluated whether the Commission’s obesity definition can better predict clinical risk among people with metabolic dysfunction–associated steatotic liver disease (MASLD).
MASLD, a growing global health problem linked to metabolic dysregulation, often develops in individuals whose metabolic risk profiles may not be fully captured by traditional weight-based thresholds. By contrast, the Lancet Commission emphasizes a clinical approach intended to reflect obesity’s health impact more accurately.
To address this question, the team applied the Commission’s clinical obesity criteria to an Asian MASLD cohort. They then examined how classification under the new definition related to subsequent clinical outcomes. The central goal was to determine whether this updated obesity construct identifies patients with higher likelihood of adverse disease trajectories.
While obesity is frequently treated as a simple matter of body mass index, MASLD outcomes are shaped by a broader metabolic context. The study therefore tests a more nuanced definition, aiming to improve risk stratification beyond conventional anthropometric cutoffs alone.
The investigators report associations between being categorized as clinically obese under the Lancet framework and clinically meaningful endpoints in MASLD. If validated, the results could influence how clinicians evaluate risk in routine practice, particularly in regions where metabolic risk patterns may differ from those seen in Western cohorts.
From a scientific perspective, the work highlights a shift toward phenotype- and risk-oriented definitions in chronic disease classification. Such approaches may help clinicians target monitoring and interventions more precisely, especially for patients who fall into ambiguous weight categories but still carry substantial metabolic burden.
Overall, the findings support the idea that adopting newer clinical obesity definitions could refine MASLD management strategies. Further validation in diverse populations and settings will be needed to confirm generalizability and to determine how best to integrate the criteria into guidelines.
Subject of Research: Metabolic dysfunction–associated steatotic liver disease (MASLD) and clinical obesity definitions
Article Title: Adopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)
Article References: Ho, K.CY., Hui, R.WH., Wu, T.KH. et al. (2026). International Journal of Obesity. https://doi.org/10.1038/s41366-026-02173-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41366-026-02173-5
Tags: Asian MASLD patient studybody composition and metabolic healthclinical obesity definitionclinical outcomes in MASLDLancet diabetes and endocrinologyliver disease prognosis and obesityMASLD risk assessmentmetabolic dysfunction-associated steatotic liver diseasemetabolic dysregulation and liver healthnovel obesity diagnostic criteriaobesity classification in liver diseaserisk stratification in obesity
